THREE PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV

HIV 初始治疗的三种蛋白酶抑制剂保留方案

• 批准号: 7377417
• 负责人: Christopher D Pilcher
• 金额: $ 6.44万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377417
• 关键词: THREE; PROTEASE; INHIBITOR; SPARING; REGIMENS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. ACTG-A5095 - The purpose of this study is to learn: How well each combination of drugs lowers the amount of HIV in blood and keeps it low; and How well drug combinations are tolerated; and How safe the combinations of drugs are.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。ACTG-A5095-这项研究的目的是了解：每种药物组合降低血液中艾滋病毒数量并保持在较低水平的效果如何；药物组合的耐受性有多好；以及药物组合的安全性。